Mass cytometry panel optimization through the designed distribution of signal interference
Chikara Takahashi, Amelia Au‐Yeung, Franklin K. Fuh et al. · Cytometry Part A · 2016
Mass cytometry is capable of measuring more than 40 distinct proteins on individual cells making it a promising technology for innovating biomarker discovery. However, in order for this potential to be fully realized, best practices in panel design need to be further defined in order to achieve consistency and reproducibility in data analysis. Of particular importance are controls that reveal, and panel design principles that mitigate the effects of signal interference or overlap. We observed a disparity between the staining profiles of two noncompeting anti- integrin β7 mAbs and hypothesized that signal interference was responsible. A mass-minus-one (MMO) control was applied and demonstrated that signal overlap caused the perceived interclonal discrepancy in β7 expression. Panel redesign in consideration of mass-cytometry specific interference dynamics dramatically improved concordance between both mAbs by redistributing background signals caused by overlap. These studies visualize how signal overlap can complicate mass cytometry data interpretation and demonstrate how the rational distribution of interference can greatly improve panel design and data quality. © 2016 International Society for Advancement of Cytometry.
Cited by 85 works. doi:10.1002/cyto.a.22977 Open-access PDF
Authors
- Chikara Takahashi
- Amelia Au‐Yeung
- Franklin K. Fuh
- Teresa Ramirez‐Montagut
- Chris Bolen
- W. Rodney Mathews
- William E. O’Gorman
References
- Single-Cell Mass Cytometry of Differential Immune and Drug Responses Across a Human Hematopoietic Continuum
- Spectral compensation for flow cytometry: Visualization artifacts, limitations, and caveats
- Expression of CD57 defines replicative senescence and antigen-induced apoptotic death of CD8+ T cells
- Normalization of mass cytometry data with bead standards
- The Binding Specificity and Selective Antagonism of Vedolizumab, an Anti-α4β7 Integrin Therapeutic Antibody in Development for Inflammatory Bowel Diseases
- A deep profiler's guide to cytometry
- Highly multiparametric analysis by mass cytometry
- Etrolizumab as induction therapy for ulcerative colitis: a randomised, controlled, phase 2 trial
- Flow cytometry controls, instrument setup, and the determination of positivity
- A platinum‐based covalent viability reagent for single‐cell mass cytometry